Evidence map›Paper›PMID 34537504›Full record

ArticleAmerican journal of otolaryngology

The value of tracheostomy of critically ill COVID-19 patients - A multicentral study.

Tal Rozenblat, Ella Reifen, Avi Benov, Chanan Shaul, Uri Neuman, Dana Karol, Reut Schvartz, Gideon Bachar

Abstract readMulticenter Study
In one paragraph

Article in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Tracheostomy is associated with decreased in-hospital mortality during severe COVID-19 infection.World journal of otorhinolaryngology - head and neck surgery · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tal RozenblatDepartment of Otolaryngology, Head and Neck Surgery, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: talda1@clalit.org.il.
Ella ReifenDepartment of Otolaryngology, Head and Neck Surgery, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel. Electronic address: ellar@clalit.org.il.
Avi BenovIsrael Defense Forces, Medical Corps, Tel Hasomer, Ramat Gan, Israel; The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Electronic address: avi.benov@gmail.com.
Chanan ShaulDepartment of Otolaryngology-Head and Neck Surgery, Shaare Zedek Medical Center Affiliated with the Hebrew University Medical School, Jerusalem, Israel. Electronic address: hananshaul@gmail.com.
Uri NeumanDepartment of Otolaryngology, Meir Medical Center, Kfar Saba, Israel. Electronic address: Uri.neuman@gmail.com.
Dana KarolDivision of Anesthesia, Intensive Care, and Pain Management, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: danaka8@gmail.com.
Reut SchvartzDivision of Anesthesia, Intensive Care, and Pain Management, Tel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: reutschvartz@gmail.com.
Gideon BacharDepartment of Otolaryngology, Head and Neck Surgery, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: GideonB@clalit.org.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTracheostomy is an aerosol-generating procedure, thus performing it during the COVID-19 pandemic arises considerations such as the most appropriate timing and the patients to whom it is suitable. Medical teams lack sufficient data to assist determining whether or not to conduct tracheostomy, its short- and long-term implications are not fully understood. This study aims to shed light on the critically ill COVID-19 patients that require tracheostomy, and to investigate its value.

methodsA retrospective multicentral case-control study of 157 hospitalized critically ill COVID-19 patients, among whom 30 patients went through tracheostomy and consisted of our study group.

resultsThe mean age was similar between study and control groups (68.9 ± 12.7 years vs 70.5 ± 15.8 years, p = 0.57), as well as comorbidity prevalence (56.7% vs 67.7%, p = 0.25). Patients in the study group were hospitalized for longer duration until defined critically ill (5 ± 4.3 vs 3 ± 3.9 days; p = 0.01), until admitted to the intensive care unit (6 ± 6.6 vs 2.5 ± 3.7 days respectively; p = 0.005), and until discharged (24 ± 9.7 vs 10.7 ± 9.1 days, p < 0.001). Mortality rate was lower in the study group (30% vs 59.8%, p = 0.003). Kaplan Meier survival analysis revealed a statistically significant difference in survival time between groups (Log rank chi-sq = 20.91, p < 0.001) with mean survival time of 41 ± 3.1 days vs 21 ± 2.2 days. Survival was significantly longer in the study group (OR = 0.37, p = 0.004).

conclusionTracheostomy allows for more prolonged survival for gradually deteriorating critically ill COVID-19 patients. This should be integrated into the medical teams' considerations when debating whether or not to conduct tracheostomy.

Indexed as

TracheostomyAgedCOVID-19Critical IllnessFemaleHumansLength of StayMalePandemicsPneumonia, ViralSARS-CoV-2Survival RateCOVID19Mechanical ventilationSARS-Cov-2Tracheostomy

Identifiers

PMID34537504
PMCPMC8440006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.